课题基金 / 基金详情

NES保有蛋白の核外移行阻害を標的とする新規医薬リード化合物の探索

NES保有蛋白の核外移行阻害を標的とする新規医薬リード化合物の探索
寻找靶向抑制 NES 蛋白核输出的新型药物先导化合物
批准号:
13672213
负责人:
MURAKAMI Nobutoshi
金额:
$2.3万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2001
资助国家:
日本
项目状态:
已结题
起止时间:
2001 至 2002

项目摘要

项目成果

MURAKAMI Nobutoshi的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Recently, some proteins with nuclear export signal (NES), which is a characteristic sequence of amino acids, were shown to be exported from nucleus to cytoplasm with the aid of NES receptor protein CRM1. Mitogenactivated protein kinase kinase (MAPKK) and Rev were shown to be representative NES possessing proteins and play important roles in cytoplasm after export from nucleus. The former is concerned with proliferation of various tumor cells, the latter is required by replication of HIV 1 virus. In addition, inhibition of NES receptor, CRM1, led to suppress both proliferation of the tumor cells and replication of HIV1 virus potently. Up to date, leptomycin B (2) and callystatin A (3) have been only clarified to be inhibitors of CRM1. In this context, we constructed an assay system to search for another NES inhibitor by using the NLS GFP NES transformed yeast and disclosed a new NES inhibitor, vartrate (1), from Valerianae Radix through bioassayguided separation. By using the biotinylated probe derived from callystatin A (3), varflate (1) was presumed to inhibit export of the NES possessing proteins through binding to the Cys 529 in CRM1 in the same fashion as 2 and 3. Furtherriiore, the binding site of 1 to CRM1 was elucidated to be an epoxy moiety from the reactant of 1 and N acetylcysteine methyl ester
期刊论文(24)
专著(0)
科研奖励(0)
会议论文
N.Murakami et al.: "Synthesis of stable analogs in blood and conformational analysis of arenastatin A, a potent cytotoxic spongean depsipeptide"Tetrahedron. 57(19). 4323-4336 (2001)
N.Murakami 等人:“血液中稳定类似物的合成和阿那他汀 A(一种有效的细胞毒性海绵缩酚肽)的构象分析”四面体。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
N,Murakami: "New Semi-synthetic Quassinoids with Leading in Vivo Anti-malarial Activity"J. Med. Chem. 46(4). 638-641 (2003)
N,Murakami:“具有领先体内抗疟疾活性的新型半合成Quassinoids”J。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
N,Murakami: "Exploration for anti-cancer leads through synthetic approach utilizing biologi cally active natural products as seed principles"Natural Medicines. 56(3). 73-77 (2002)
N,Murakami:“通过利用具有生物活性的天然产物作为种子原理的合成方法来探索抗癌”天然药物。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
N.Murakami et al.: "Total synthesis of agosterol A, an MDR-modulator from a marine sponge"Chem. Eur. j.. 7(12). 2663-2670 (2001)
N.Murakami 等人:“来自海绵的 MDR 调节剂阿戈甾醇 A 的全合成”Chem.
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
17
    Elucidation of new anti-tumor and anti-HIV target proteins by using probe molecules derived from bioactive natural products
    • 批准号:
      21603009
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.0万
    • 财政年份:
      2009
    • 负责人:
      MURAKAMI Nobutoshi
    • 依托单位:
    Exploration for New Medicinal Leads by Use of Natural Products Inhibiting Nuclear Export of Proteins as Scaffolds
    • 批准号:
      19590100
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.91万
    • 财政年份:
      2007
    • 负责人:
      MURAKAMI Nobutoshi
    • 依托单位:
    Search for Medicinal Leads Inhibiting Nuclear Export of NES-containing Protein
    • 批准号:
      16590007
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.24万
    • 财政年份:
      2004
    • 负责人:
      MURAKAMI Nobutoshi
    • 依托单位:
    Exploration for Traditional Anti-infectious Medicinal Plants in Central Africa
    • 批准号:
      16406003
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $8.26万
    • 财政年份:
      2004
    • 负责人:
      MURAKAMI Nobutoshi
    • 依托单位:
    国内基金
    海外基金
    抑制CRM1介导的NCOR2-HDAC3复合体核输出在阿尔茨海默病中的作用及相关机制研究
    • 批准号:
      82371194
    • 项目类别:
      面上项目
    • 资助金额:
      49万元
    • 批准年份:
      2023
    • 负责人:
      杜烨鸿
    • 依托单位:
    CRM1介导ASC出核促进炎症小体活化的机制研究
    • 批准号:
      82371768
    • 项目类别:
      面上项目
    • 资助金额:
      48万元
    • 批准年份:
      2023
    • 负责人:
      王夏琼
    • 依托单位:
    筛选设计非共价结合的更低毒性的CRM1抑制剂
    • 批准号:
      82273850
    • 项目类别:
      面上项目
    • 资助金额:
      76万元
    • 批准年份:
      2022
    • 负责人:
      孙庆祥
    • 依托单位:
    神经营养因子GDNF调控Survivin/CRM1在角膜缘干细胞促进组织修复再生的机理研究
    • 批准号:
      81970771
    • 项目类别:
      面上项目
    • 资助金额:
      55.0万元
    • 批准年份:
      2019
    • 负责人:
      董诺
    • 依托单位: